Allogene Therapeutics ALLO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$173.76M+31.1% | -$190.89M+25.9% | -$212.02M+25.2% | -$236.91M+15.2% | -$252.32M+13.7% | ||
| $12.13M-8.0% | $12.36M-9.4% | $12.54M-9.7% | $12.65M-11.3% | $13.18M-7.5% | ||
| $33.74M-35.1% | $37.64M-27.3% | $42.39M-21.7% | $47.12M-16.0% | $51.99M-12.0% | ||
| -$109.23M+44.6% | -$149.25M+25.5% | -$158.35M+27.1% | -$172.77M+24.5% | -$197.33M+13.1% | ||
| $296K-62.3% | $386K-44.4% | $643K+4.0% | $829K+312% | $785K+60.5% | ||
| $59.8M— | $95.56M— | $116.88M— | —— | —— | ||
| $37.29M-71.1% | $30.16M-74.2% | $28.04M-74.8% | $25.48M-77.8% | $129.02M+34.9% | ||
| —— | —— | —— | —— | —— | ||
| -$109.53M+44.7% | -$149.63M+25.6% | -$158.99M+27.0% | -$173.6M+24.2% | -$198.12M+12.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Allogene Therapeutics generate?
- Allogene Therapeutics (ALLO) generated -$109.2M in operating cash flow over the trailing twelve months.
- What is Allogene Therapeutics's free cash flow?
- After $296.0K of capital expenditures, Allogene Therapeutics's free cash flow was -$109.5M over the trailing twelve months, up 44.7% year over year.
- Where does Allogene Therapeutics's cash flow data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.